{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:36:52Z","timestamp":1791113812047,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T00:00:00Z","timestamp":1169683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T00:00:00Z","timestamp":1169683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1038\/sj.leu.2404533","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T11:56:49Z","timestamp":1169726209000},"page":"421-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines"],"prefix":"10.1038","volume":"21","author":[{"given":"D J","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"van Hensbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c8","family":"Moravcsik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J V","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,1,25]]},"reference":[{"key":"BF2404533_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561\u2013566.","journal-title":"Nat Med"},{"key":"BF2404533_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A . Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493\u2013502.","journal-title":"Nat Rev Drug Discov"},{"key":"BF2404533_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031\u20131037.","journal-title":"N Engl J Med"},{"key":"BF2404533_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BF2404533_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423\u20131432.","journal-title":"N Engl J Med"},{"key":"BF2404533_CR6","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","volume":"99","author":"HM Kantarjian","year":"2002","unstructured":"Kantarjian HM, Cortes J, O'Brien S, Giles FJ, AlBitar M, Rios MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547\u20133553.","journal-title":"Blood"},{"key":"BF2404533_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75\u201385.","journal-title":"Lancet Oncol"},{"key":"BF2404533_CR8","first-page":"237","volume":"6","author":"PA Svingen","year":"2000","unstructured":"Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA et al. Effects of the bcr\/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 2000; 6: 237\u2013249.","journal-title":"Clin Cancer Res"},{"key":"BF2404533_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002800050817","volume":"42","author":"TW Schulte","year":"1998","unstructured":"Schulte TW, Neckers LM . The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42: 273\u2013279.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2404533_CR10","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood-2005-07-2966","volume":"107","author":"J Chandra","year":"2006","unstructured":"Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M et al. Adaphostin-induced oxidative stress overcomes BCR\/ABL mutation-dependent and -independent imatinib resistance. Blood 2006; 107: 2501\u20132506.","journal-title":"Blood"},{"key":"BF2404533_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00280-005-0094-4","volume":"57","author":"M Li","year":"2006","unstructured":"Li M, Wang H, Hill DL, Stinson S, Veley K, Grossi I et al. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr\/abl. Cancer Chemother Pharmacol 2006; 57: 607\u2013614.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2404533_CR12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.leu.2403764","volume":"19","author":"A Radujkovic","year":"2005","unstructured":"Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL \u2013 Inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005; 19: 1198\u20131206.","journal-title":"Leukemia"},{"key":"BF2404533_CR13","first-page":"1799","volume":"61","author":"R Nimmanapalli","year":"2001","unstructured":"Nimmanapalli R, O'Bryan E, Bhalla K . Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61: 1799\u20131804.","journal-title":"Cancer Res"},{"key":"BF2404533_CR14","first-page":"5761","volume":"62","author":"R Nimmanapalli","year":"2002","unstructured":"Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T et al. Molecular characterization and sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17- demethoxygeldanamycin. Cancer Res 2002; 62: 5761\u20135769.","journal-title":"Cancer Res"},{"key":"BF2404533_CR15","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","volume":"100","author":"ME Gorre","year":"2002","unstructured":"Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL . BCR-ABL point mutants isolated from patients with imatinib mesylate- resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat-shock protein 90. Blood 2002; 100: 3041\u20133044.","journal-title":"Blood"},{"key":"BF2404533_CR16","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","volume":"105","author":"P George","year":"2005","unstructured":"George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768\u20131776.","journal-title":"Blood"},{"key":"BF2404533_CR17","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1124\/mol.104.007831","volume":"67","author":"M Rahmani","year":"2005","unstructured":"Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol 2005; 67: 1166\u20131176.","journal-title":"Mol Pharmacol"},{"key":"BF2404533_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1182\/blood.V99.2.664","volume":"99","author":"BM Mow","year":"2002","unstructured":"Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ et al. Effects of the Bcr\/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002; 99: 664\u2013671.","journal-title":"Blood"},{"key":"BF2404533_CR19","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1182\/blood-2003-02-0562","volume":"102","author":"J Chandra","year":"2003","unstructured":"Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM et al. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003; 102: 4512\u20134519.","journal-title":"Blood"},{"key":"BF2404533_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00280-002-0507-6","volume":"50","author":"IA Avramis","year":"2002","unstructured":"Avramis IA, Christodoulopoulos G, Suzuki A, Laug WE, Gonzalez-Gomez I, McNamara G et al. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother Pharmacol 2002; 50: 479\u2013489.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2404533_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/sj.onc.1207248","volume":"23","author":"C Yu","year":"2004","unstructured":"Yu C, Rahmani M, Almenara J, Sausville EA, Dent P, Grant S . Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1\/MEK\/ERK- and AKT-dependent process. Oncogene 2004; 23: 1364\u20131376.","journal-title":"Oncogene"},{"key":"BF2404533_CR22","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1038\/sj.onc.1208796","volume":"24","author":"DJ Barnes","year":"2005","unstructured":"Barnes DJ, Schultheis B, Adedeji S, Melo JV . Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 2005; 24: 6432\u20136440.","journal-title":"Oncogene"},{"key":"BF2404533_CR23","doi-asserted-by":"publisher","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","volume":"65","author":"DJ Barnes","year":"2005","unstructured":"Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912\u20138919.","journal-title":"Cancer Res"},{"key":"BF2404533_CR24","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1002\/j.1460-2075.1994.tb06934.x","volume":"13","author":"JH Kabarowski","year":"1994","unstructured":"Kabarowski JH, Allen PB, Wiedemann LM . A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13: 5887\u20135895.","journal-title":"EMBO J"},{"key":"BF2404533_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.leukres.2006.01.005","volume":"30","author":"G Dasmahapatra","year":"2006","unstructured":"Dasmahapatra G, Nguyen TK, Dent P, Grant S . Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr\/Abl. Leuk Res 2006; 30: 1263\u20131272.","journal-title":"Leuk Res"},{"key":"BF2404533_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood-2005-06-2302","volume":"107","author":"G Dasmahapatra","year":"2006","unstructured":"Dasmahapatra G, Rahmani M, Dent P, Grant S . The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 2006; 107: 232\u2013240.","journal-title":"Blood"},{"key":"BF2404533_CR27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/00001813-199611000-00001","volume":"7","author":"G Kaur","year":"1996","unstructured":"Kaur G, Sausville EA . Altered physical state of p210bcr-abl in tyrphostin AG957-treated K562 cells. Anticancer Drugs 1996; 7: 815\u2013824.","journal-title":"Anticancer Drugs"},{"key":"BF2404533_CR28","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1349-7006.2006.00269.x","volume":"97","author":"N Orsolic","year":"2006","unstructured":"Orsolic N, Golemovic M, Quintas-Cardama A, Scappini B, Manshouri T, Chandra J et al. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci 2006; 97: 952\u2013960.","journal-title":"Cancer Sci"},{"key":"BF2404533_CR29","doi-asserted-by":"publisher","first-page":"24273","DOI":"10.1074\/jbc.M002094200","volume":"275","author":"M Sattler","year":"2000","unstructured":"Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275: 24273\u201324278.","journal-title":"J Biol Chem"},{"key":"BF2404533_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1158\/1078-0432.CCR-05-1194","volume":"12","author":"GV Georgakis","year":"2006","unstructured":"Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A . Inhibition of heat-shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006; 12: 584\u2013590.","journal-title":"Clin Cancer Res"},{"key":"BF2404533_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1046\/j.1365-2141.2003.04330.x","volume":"121","author":"J Topaly","year":"2003","unstructured":"Topaly J, Schad M, Laufs S, Melo JV, Zeller WJ, Fruehauf S . Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL. Br J Haematol 2003; 121: 672\u2013673.","journal-title":"Br J Haematol"},{"key":"BF2404533_CR32","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria Jr","year":"1996","unstructured":"Ilaria Jr RL, Van Etten RA . P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996; 271: 31704\u201331710.","journal-title":"J Biol Chem"},{"key":"BF2404533_CR33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","volume":"86","author":"T Skorski","year":"1995","unstructured":"Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G et al. Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726\u2013736.","journal-title":"Blood"},{"key":"BF2404533_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/sj.embor.7400536","volume":"6","author":"A Ress","year":"2005","unstructured":"Ress A, Moelling K . Bcr is a negative regulator of the Wnt signalling pathway. EMBO R 2005; 6: 1095\u20131100.","journal-title":"EMBO R"},{"key":"BF2404533_CR35","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.leu.2404245","volume":"20","author":"AM Martelli","year":"2006","unstructured":"Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. Phosphoinositide 3-kinase\/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20: 911\u2013928.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404533","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:45:48Z","timestamp":1648781148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,25]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["BF2404533"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404533","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,25]]},"assertion":[{"value":"1 November 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}